## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

FRIEDRICH et al.

Serial No. 09/235,242

Filed:

January 22, 1999

For: PREPARATION OF BETA-ALKOXYNITRILES

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

**AMENDMENT** 

Sir:

Group Art Unit: 1626

Examiner: Stockton

OCT 3 0 2002 OCT 3 0 2002 OH CENTER 1600/2900

27/E UHanni 1//8/12

Further to the decision by the Board of Patent Appeals and Interferences, applicants are filing the present amendment along with the attached Request for Continued Application.

NOV 0 I 2002 CH CENTED 2900

Approved to se through 10/31/2002/OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co

REQUEST	
FOR	
EVARAINATIO	N.

## TINUED EXAMINATION (RCE) TRANSMITTAL

Address to: **Commissioner for Patents Box RCE** Washington, DC 20231

Herbert B. Keil

Name (Print/Type)

Signature

meets in or information amount a deployer a term of the	
Application Number	09/235,242
Filing Date	1/22/99
First Named Inventor	FRIEDRICH et al.
Art Unit	1626
Examiner Name	Stockton
Attorney Docket Number	48746

October 21, 2002

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2. Submission required under 37 CFR 1.114 a. Previously submitted Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on (Any unentered amendment(s) referred to above will be entered). Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_ Other b. X Enclosed Information Disclosure Statement (IDS) X Amendment/Reply Affidavit(s)/Declaration(s) Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required.) b. Other Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to 11-0345 Deposit Account No. RCE fee required under 37 CFR 1.17(e) 10/28/2002 RUDNDAF1 00000021 09235242 Extension of time fee (37 CFR 1.136 and 1.17) ANY DEFICIENCY IN FEES 740,00 09 iii. x Other 01 FC:1801 740.00 b. X Check in the amount of \$\_ enclosed c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED 18,967 Herbert B. Keil Registration No. (Attomey/Agent) Name (Print /Type) October 21, 2002 Signature CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as frst class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

Date